For comments, suggestions
Created with Raphaël 2.1.0 15.06.2016 Filing date 02.08.2017 Validation fee payment 31.01.2018 (A1) Patent application published 27.10.2019 AGEPI application filing date 31.01.2020 (T2) Translation of the validated European patent 15.06.2023 Valid until 29.02.2024 (MM4E) Forfeiture of rights 31.01.2025 (MM4E) Forfeiture of rights

Patent lapsed


(210)Number of the EPO application16731640
(220)Filing date of the EPO application2016.06.15
(80)EPO patent specification publication (B)EPB nr. 31/2019, 2019.07.31
(110)EPO patent number3240554
(11)Number of the documentMD 3240554 T2
(21)Number of the applicatione 2017 0262
(71)Name(s) of applicant(s), code of the country4D Pharma Research Limited, GB;
(72)Name(s) of inventor(s), code of the countryGRANT George, GB;
PATTERSON Angela Margaret, GB;
MULDER Imke, GB;
MCCLUSKEY Seanin, GB;
RAFTIS Emma, GB;
(73)Name(s) of owner(s), code of the country4D Pharma Research Limited, GB;
(54)Title of the inventionBlautia stercosis and wexlerae for use in treating inflammatory and autoimmune diseases
(13)Kind-of-document code T2
(51)International Patent Classification A61K 35/74 (2015.01.01); C12N 1/20 (2006.01.01); A61P 1/00 (2006.01.01); A61P 11/06 (2006.01.01); A61P 29/00 (2006.01.01); A61P 19/02 (2006.01.01); A61P 25/28 (2006.01.01); A61K 35/745 (2015.01.01)
(19)CountryGB
(41)Date of publication of the application2018.01.31
(49)Date of publication of the translation of the validated European patent specification2020.01.31
(30)Priority201510466, 2015.06.15, GB; 201520508, 2015.11.20, GB; 201606810, 2016.04.19, GB
(74)Patent attorney(Procedură) PARASCA Dumitru, str. Eminescu nr. 40, ap. 13, c/p 28, MD-2012, Chişinău, Republica Moldova
(86)International applicationPCT/GB2016/051770, 2016.06.15
(87)International publicationWO 2016/203218, 2016.12.22
Up
/Inventions/details/3240554